Drug
Verducatib
Verducatib: highest development phase Phase 3, developed by Boehringer Ingelheim. 3 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Boehringer Ingelheim
Trials
| Drug | Phase | Indication |
|---|---|---|
| verducatib NCT07915219 | Phase 3 | Bronchiectasis |
| Verducatib NCT07907991 | Phase 3 | Chronic Obstructive Pulmonary Disease |
| Verducatib NCT07760246 | Phase 1 |
Latest
No recent events.
Follow Verducatib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.